Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PRODUCT LIABILITY LEGISLATION: CLAIMANTS RIGHTS WHEN MFR. IS UNKNOWN would be studied by an expert panel authorized by S 44, Sen. Kasten's (D-Wisc.) uniform product liability law that passed the Senate Commerce Cmte. March 27. Under an amendment proposed by Cmte. Chairman Packwood (R-Ore.), the three man panel would "study the need for federal legislation" providing compensation to claimants who are unable to recover in civil action because "the product that caused the harm was unreasonably dangerous (as defined in the act) but the mfr. could not be identified." The panel would also examine the need for federal legislation providing compensation to claimants unable to recover in any civil action because "the mfr. of the product did not know and could not in the exercise of reasonable prudence have known at the relevant point in time (as defined in [the act]) about the danger that caused the harm." The issues are similar to those involved in on-going cases involving DES, where claimants are trying to recover damages collectively from a group of mfrs. of DES, although they are unable to identify the specific mfr. of the drug product allegedly responsible for injury. The legislation cleared the Commerce Cmte. by a vote of 11-yes, 5-no, and one "present." The bill reported to the Senate floor leaves intact the "Robins amendment," so called for its bearing on Dalkon Shield litigation. Under that provision, added to the bill last fall, punitive damages may be awarded only when a claimant establishes that the "harm suffered was the result of the reckless disregard of the mfr. or product seller for the safety of product users." The provision states, however, that "punitive damages may not be awarded in the absence of a compensatory award." The bill defines "reckless disregard" as "conduct manifesting a conscious, flagrant indifference to the safety of those persons who might be harmed by a product and constituting an extreme departure from accepted practice. A negligent choice among alternative product designs or warnings, when made in the ordinary course of business, does not by itself constitute 'reckless disregard.'"

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts